ACUTE HEPATIC FAILURE (Prognosis & Liver transplantation)
|
|
|
- Ginger Golden
- 10 years ago
- Views:
Transcription
1 ACUTE HEPATIC FAILURE (Prognosis & Liver transplantation) DR.NASSER E.DARYANI PROFESSOR OF TEHRAN MEDICAL UNIVERSITY
2 Definition Complex syndrome of acute liver injury with INR>1.5 and any degree of encephalopathy in a patient without preexisting cirrhosis Duration of illness less than 26 weeks Fulminant liver failure: duration less than 8 weeks Exceptions for preexisting cirrhosis: Wilson s disease Vertically transmitted hepatitis B Autoimmune hepatitis
3 Introduction Acute liver failure (ALF) is a rare condition in which rapid deterioration of liver function results in altered mentation and coagulopathy in previously normal individuals. The most prominent causes include drug induced liver injury, viral hepatitis, autoimmune liver disease and shock or hypoperfusion; many cases (20%) have no discernible cause. Paracetamol remains the most common aetiology of acute liver failure in developed countries, whereas acute viral aetiologies predominate elsewhere.
4 Acute liver failure in USA Actaminophen overdose(46%) Indeterminant(14%) Drug related(11%) HBV(7%) Autoimmune hepatitis(5%) Ischemia(4%) HAV(3%) Wilson(2%) Other causes(7%) cxds
5 267 patients in 17 hospitals from Viral hepatitis in 37% (mostly HBV) Unknown cause in 32% Drug and toxins in 19% (acetaminophen in 2%) Overall survival 58%. Liver Transplantation 2007;13:
6 prognosis Cause is one of the most important predictors of ALF Outcome. The lowest mortality is seen with APAP hepatotoxicity (30%) and hepatitis A virus (50%). In contrast, the mortality in the remainder of causes is abysmal (80 100%) Paradoxically, those with more rapid development of hepatic encephalopathy appear to have a better outcome compared with those with a longer interval between development of symptoms and encephalopathy.(1) (1) Anne M. Larson; Diagnosis and management of acute liver failure; Current Opinion in Gastroenterology 2010.
7 Outcome Based on Days of Symptoms Prior to Occurrence of Encephalopathy Hyperacute (0-7 days) Transplant free survival 30% Acute (7-28 days) Transplant free survival 33% Subacute (>28 days) Transplant free survival 14%
8 Prognosis(Con t) Prognostic scoring systems, although derived from data on relatively large numbers of patients, still fail to achieve success, given the wide variety of etiologies that lead to this end stage syndrome. The traditional King s College Hospital criteria have been the most commonly utilized & most frequently tested of the numerous propose prognostic criteria for ALF. (PPV<70% to 100% & NPV:25-94%)
9 Prognostic Factors: King s College Criteria Acetaminophen cases Arterial PH < 7.3 or Arterial lactate>3.5 at 4 hrs or Arterial lactate>3 at 12 hrs or INR>6.5 & Cr>3.4 & Stage 3 or 4 encephalopathy Non-acetaminophen cases INR>6.5 or Any 3 of the followings: Age<10 or >40 yrs Duration of jaundice>7 d Total Bili>17.5 INR>3.5 Etiology: idiosyncratic drug, halothane, idiopathic, non-a non-b hepatitis Lancet 1993;342:273-5
10 Prognosis cont King's College Hospital criteria* for liver transplantation in fulminant hepatic failure Acetaminophen-induced disease Arterial ph <7.3 (irrespective of the grade of encephalopathy) OR Grade III or IV encephalopathy AND Prothrombin time >100 seconds AND Serum creatinine >3.4mg/dL All other causes of fulminant hepatic failure Prothrombin time >100 seconds (irrespective of the grade of encephalopathy) OR Any three of the following variables (irrespective of the grade of encephalopathy) 1. Age <10 years or >40 years 2. Etiology: non-a, non-b hepatitis, halothane hepatitis, idiosyncratic drug reactions 3. Duration of jaundice before onset of encephalopathy >7 days 4. Prothrombin time >50 seconds 5. Serum bilirubin >18 mg/dl * A statistical model for predicting the outcome in patients with FHF
11 Prognosis(Con t) King's College Hospital Criteria (KCHC) had its greatest specificity and PPV in patients with acetaminophen overdose. This model has great specifity and positive/negative predictive value,but poor sensitivity
12 Modified criteria of KCH for paracetamol acute liver failure etiology Strongly consider listing for OLT if: Arterial lactate >3.5 mmol L after early fluid resuscitation List for transplantation if: Arterial ph <7.3, or arterial lactate >3.0 mmol L after adequate fluid resuscitation List for transplantation if all 3 of the following occur within a 24-h period: Grade III IV HE PT >100 s (INR >6.5) Serum creatinine >300 mcmol L
13 Factors Predictive of Survival & Neurological Sequel 500 pts with ALF (350 with FHF) from pts had no HE, 98% survived Cause of death: cerebral edema(44%), sepsis (29%) Compared two groups of pre and post 1996 Lower rate of HBV related, stage IV HE & brain death Higher rate of acetaminophen related, better post OLT survival Controlled for hepatic coma & organ failure, better outcome was secondary to earlier ICU admission & less HBV infection EASL annual meeting, April 2007
14 Potentially helpful indicator of good(transplant free)prognosis in patiant with ALF 1:acetaminophen 2:ischemia 3:HAV (58-64%) cxds
15 Potentially Helpful Indicators* of Poor (Transplant free) Prognosis in Patients With ALF Etiology Idiosyncratic drug injury Acute hepatitis B (and other non-hepatitis A viral infections) Autoimmune hepatitis Mushroom poisoning Wilson disease Budd-Chiari syndrome Indeterminate cause ( 20-25%) Coma grade on admission III IV
16 52% 308 pts in 17 centers Median age 38 yrs 73% women 39% acetaminophen toxicity 13 % Idiosyncratic drug toxicity 17% undetermined 12% hepatitis B & A 2002;137:
17 other score Viral(clichy score) age<30 factorv<20%,grade3 to 4 encephalopathy MELD score(meld>30) APACHE II(score>15) Ammonia level(all)> umol/l A fetoprotein(acetaminophen)afp<3.9ug/lday1
18 Alternative prognostic variables suggested for use in acute liver failure Prognostic variable etiology Predictor of poor prognostic outcome Sen. Spec. Refs KCC All See slide Clichy criteria All HE + Factor V < 20% (age <30 year) or <30% (age >30 year) Factor V; factor VIII V ratio Acetamin Factor VIII V ratio >30 Factor V < 10% Phosphate Acetamin PO4> 1.2 mmol L on day 2 or 3 postoverdose APACHE II All APACHE II > Gc-globulin All Gc-globulin <100 mg L Lactate Acetamin Admission arterial lactate >3.5 or >3.0 mmol L after fluid resuscitation a-fetoprotein Acetamin AFP <3.9 mcg L 24 h postpeak ALT MELD Acetamin Non-acet. MELD >33 at onset of HE MELD >
19 Prognosis(Con t) In a study of 127 patients with ALF,serum ferritin was measured on days 1&3 after hospitalization. Patients who spontaneously survived (n = 64) had larger median reductions in serum ferritin from day 1 to 3 compared with those who underwent OLT (n=32) (p<0 05) or those who died without OLT (n=31) (p<0.0001). This study concluded that Patients with initial levels of serum ferritin greater than 20,000 mcg/l have a high probability of survival without OLT. Significant reductions of serum ferritin during the initial course of ALF likely indicate return of liver function.(1) (1)Jessica D. Korman, Frank V. Schiodt, and et al; Elevation of Serum Ferritin and Survival of Patients with Acute Liver Failure, Gastroenterology, Volume 124, Issue 4, Supplement 1, April 2003, Page A756
20 Treatment efficacy Highly effective: 1:(N-acetylcystein in acetaminophen toxicity, 2: Promt delivery in AFL of pregnancy&help 3: penicillin G in Amanita toxicity cxds
21 Efficacy of tretment Less effective 1:Acyclovir in herpes virus 2:Steroid in autoimmune hepatitis 3:Nucleoside analogue in hepatitis B cxds
22 Prognosis(con t) In patients with ALF, there were no significant differences in survival or rate of liver transplantation among racial and ethnic groups except for transplantation in Hispanics.(1) Data published in Gastroenterology indicate that intravenous NAC improves tranplant-free survival in patients with early stage non-acetaminophen-related acute liver failure. However, patients with advanced coma grades do not benefit from NAC and typically require emergency liver transplantation.(2) (1) KIMBERLY A. FORDE, K. RAJENDER REDDY, ANDREA B. TROXELand the ACUTE LIVER FAILURE STUDY GROUP; Racial and Ethnic Differences in Presentation, Etiology, and Outcomes of Acute Liver Failure in the United States, CLINICALGASTROENTEROLOGY AND HEPATOLOGY 2009;7: (2) N-Acetylcysteine Improves Transplant-Free Survival ; Gastroenterology;2009:137(3):856-64
23 Acetaminophen Toxicity Most ingestions leading to ALF exceeds 10 g/day Severe toxicity reported with 3-4 g/day in alcoholics or malnourished patients Low or absent level does not rule it out Very high AST & ALT (>3500) is highly suggestive Early rise of serum AFP indicates good prognosis Fall of serum PO4 indicates improving
24 Drug-inducedALF Recipients who underwent liver transplantation for drug-induced acute liver failure from 1987 through 2006 were analyzed. The leading drugs cause acute liver failure were acetaminophen, antituberculosis drugs, antiepileptics and antibiotics. Children who had acute liver failure due to antiepileptics had a substantially higher risk of death after liver transplantation in comparison with other drugs.(1) (1) Doctors Evaluate Predictors of Poor Survival after Liver Transplantation; Liver Transplantation; 2009:15(7):719-29
25 DRUG induced ALF DIALF due to antiepileptics(at age<18) and elevated serum creatinine were independent pretransplant predictors of poor survival after LT for DIALF (1) Doctors Evaluate Predictors of Poor Survival after Liver Transplantation; Liver Transplantation; 2009:15(7): cxds
26 NAC in Non-acetaminophen ALF 173 pts from ALF study randomized to receive 72 hrs of IV NAC Primary endpoint: overall survival (OS) Secondary endpoint: spontaneous (transplant free) survival (SS) No difference in OS (57/81 vs 61/92) No difference in SS (32/81 vs 25/92) No difference in SS among HE grade III-IV (2/23 vs 8/36) No difference in OS among grade III-IV (p=0.09) SS significantly better with NAC among HE I-II (30/58 vs 17/56) Abstract # 79, AASLD Annual Meeting, November 2007
27 Wilson s Disease High bilirubin Low ALP Low uric acid Hemolytic anemia AST > 4 ALT Kayser-Fleischer ring in 50% of pts
28 AST:ALT > 2.2 ( 94% sensitivity & 86% specificity) AP:TB < 4 (94% sensitivity & 96% specificity) Both criteria together (100% sensitive and specific)
29 Autoimmune Hepatitis Antibodies may be absent Liver biopsy may help with diagnosis High levels of IgG suggests the AIH Steroid may help (40-60 mg/d), or may not Liver Transplantation 2007;13:
30 Anicteric hepatitis AST > ALT Rash in 50% of patients DX: HSV IgM, HSV DNA PCR, Biopsy Highly lethal if untreated Dig Dis Sci 2000;45:
31 PREGNANCY The most recent issue of Hepatology reports that mortality of pregnant patients with acute liver failure is similar to that of nonpregnant women and girls, and men and boys, and is independent of the cause or trimester.(1) (1) Pregnancy as a Prognostic Indicator in Acute Liver Failure;Hepatology;2008:48(5):
32 OBESITY Obesity does not appear to be more prevalent in acute liver failure. However, obese and severely obese patients had significantly poorer outcomes when they developed ALF,even when controlling for age,gender,race,comorbid illness,meld score,etiology of ALF. RUTHERFORD,TIM DAVERN, J. EILEEN HAY, and et al; Influence of High Body Mass Index on Outcome in Acute Liver Failure; CLINICAL cxds GASTROENTEROLOGY AND HEPATOLOGY 2006;4:
33 PROGNOSTICATION TO GUIDE OLT IN ALF The decision to list emergently an ALF patient for OLT is rarely easy. The inherent risks associated with delaying listing for OLT must be balanced against the potential for spontaneous recovery with medical therapy alone. Accurate prognostication in ALF is therefore vital, and many proposed mathematical, serological, radiological and histological variables have been proposed
34 Alternative prognostic variables suggested for use in acute liver failure Prognostic variable etiology Predictor of poor prognostic outcome Sen. Spec. Refs KCC All See slide Clichy criteria All HE + Factor V < 20% (age <30 year) or <30% (age >30 year) Factor V; factor VIII V ratio Acetamin Factor VIII V ratio >30 Factor V < 10% Phosphate Acetamin PO4> 1.2 mmol L on day 2 or 3 postoverdose APACHE II All APACHE II > Gc-globulin All Gc-globulin <100 mg L Lactate Acetamin Admission arterial lactate >3.5 or >3.0 mmol L after fluid resuscitation a-fetoprotein Acetamin AFP <3.9 mcg L 24 h postpeak ALT MELD Acetamin Non-acet. MELD >33 at onset of HE MELD >
35 Liver transplantation OLT has been recommended for the treatment of ALF since Emergency OLT for ALF now accounts for 5 12% of all liver transplantation activity & is the only treatment to alter substantially the mortality resulting from the condition.
36 LIVER TRANSPLANTATION Patient survival following OLT for ALF is generally poorer than that in those transplanted for chronic liver failure, but is of the order of 65 80% 1 year survival.(1) (1) D. G. N. CRAIG, A. LEE, P. C. HAYES & K. J. SIMPSON, Review article: the current management of acute liver failure; Aliment Pharmacol Ther 31, cxds
37 Liver trasplantation Alternatives to standard OLT are being refined, including: 1- living donor grafts 2- auxiliary liver transplantation (where part of the native liver is left in situ after partial liver transplantation) (4) D. G. N. CRAIG, A. LEE, P. C. HAYES & K. J. SIMPSON, Review article: the current management of acute liver failure; Aliment Pharmacol Ther 31,
38 Transplantation Overall outcome not as good as chronic liver failure Patient receives allocation Status 1A FHF (HE within 8 wks of the onset of the liver disease) and vent dependent or on dialysis or INR>2 or Primary non-function of LT within 7 days or Hepatic artery thrombosis within 7 days of LT or Acute decompensated Wilson s disease or Re-listing every 7 days Role of living donor transplant is controversial (contraindicated in NY state for adult patients) United Network for Organ Sharing (UNOS) web site
39 Auxiliary Transplantation Journal of Hepatology 2007;46:
40 Liver trasplantation In the largest U.S. study, only 29% of patients received a liver graft, while 10% of the overall group (1/4 of patients listed for transplantation) died on the waiting list.(1) median waiting time to tansplantation is 3 days (1) Ostapowicz GA, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH,et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:
41 Liver transplantation Other series have reported death rates of those listed for transplant as high as 40%,despite the fact that ALF remains the one condition for which the most urgent (UNOS status 1) listing is reserved.(2) ) Brown RS Jr, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003;348: cxds
42 Results of Liver Transplantation for Acute Liver Failure in U.S Center Number of patients Study period Early patient survival(%)* One year patient survival(%) Pittsburgh Chicago Michigan NR 68 Nebraska San Francisco Philadelphia USA (Multicenter) NR 76 USA (Multicenter) NR Overall (187/233) (198/284) *early patient survival reflects discharge from the hospital following transplantation NR= not reported
43 Liver Support Systems In a randomized, controlled trial in China, the Extracorporeal Liver Assist Device (ELAD) significantly increased transplantfree survival in 69 patients with chronic hepatitis B, compared with a standard of care control therapy.
44 ELAD The ELAD passes a patient s plasma through cartridges lined with the living hepatocytes;the cells remove accumulated toxins while providing the metabolites normally produced by a healthy liver. At least 72 hours of continual treatment are necessary to detoxify the blood and restore liver metabolite levels sufficiently for the cxds patient to recover.
45 At Beijing Youan Hospital, the ELAD passes the patient s plasma through cartridges lined with living human hepatocytes.
46 Liver Support Systems Survival for patients with hours on ELAD was about 50%, but increased to almost 90% as ELAD time increased to 72 hours. After 72 hours, survival began to decline slightly. Every extracorporeal device uses up platelets, but that is easily managed,with transfusions.(1) (1) MICHELE G. SULLIVAN; Liver Assist Device: Chinese Data Exciting but PreliminaryGI & HEPATOLOGY NEWS,MARCH 2008
Approach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
Liver Failure. Nora Aziz. www.3bv.org. Bones, Brains & Blood Vessels
Liver Failure Nora Aziz www.3bv.org Bones, Brains & Blood Vessels Severe deterioration in liver function Looses ability to regenerate/repair decompensated Liver extensively damaged before it fails Equal
Acute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
Evaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
Managing LFT s in General Practice
Managing LFT s in General Practice Sulleman Moreea FRCP(Edin Edin) ) FRCS(Glasg Glasg) Consultant Gastroenterologist/Hepatologist Bradford Hospitals Trust The normal liver Managing LFT s History and examination
Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
Transmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
Viral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
Investigation and treatment of liver disease with acute onset Local hospital protocol
Alastair Baker Page 1 9/7/2013 Investigation and treatment of liver disease with acute onset Local hospital protocol Defined as EITHER sudden onset of jaundice with evidence of liver aetiology OR incidental
Alanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
National Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
The sooner the better
The sooner the better A guide to MARS the liver support therapy Liver failure and MARS therapy Developing acute liver failure or deteriorating from a chronic liver disease, thousands of people are enlisted
Evaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH
Evaluation of Liver Function tests in Primary Care Abid Suddle Institute of Liver Studies, KCH Liver Function tests Markers of hepatocellular damage Cholestasis Liver synthetic function Markers of Hepatocellular
Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
Approach to Abnormal Liver Tests
This Morning s Presentation Approach to Abnormal Liver Tests Hal F. Yee, Jr., M.D., Ph.D. Rice Distinguished Professor, UCSF Chief of Gastroenterology, SFGH [email protected] Clinical vignettes representing
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
The most serious symptoms of this stage are:
The Natural Progression of Hepatitis C The natural history of hepatitis C looks at the likely outcomes for people infected with the virus if there is no medical intervention. However, the process of trying
Indications in Hepatology and Liver Diseases
exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : [email protected] Internet : www.sananet.com
Commonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
LIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
The Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago [email protected] Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
Hepatitis C and Liver Transplantation. Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky
Hepatitis C and Liver Transplantation Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky History Known as Non-A A Non-B B Hepatitis in 1974 HCV identified
Hepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
Case Study in the Management of Patients with Hepatocellular Carcinoma
Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history
BACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
INITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
Review: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
AASLD POSITION PAPER AASLD Position Paper: The Management of Acute Liver Failure
AASLD POSITION PAPER AASLD Position Paper: The Management of Acute Liver Failure Julie Polson and William M. Lee Preamble These recommendations provide a data-supported approach. They are based on the
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
The child with abnormal liver function tests
The child with abnormal liver function tests Dr Jane Hartley Consultant Paediatric Hepatologist Birmingham Children s Hospital, UK 1 st Global Congress CIP, Paris 2011 Contents Over view of liver anatomy,
Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
Saint Francis Kidney Transplant Program Issue Date: 6/9/15
Kidney Transplant Candidate Informed Consent Education Here are educational materials about Kidney Transplant. Please review and read these before your evaluation visit. The RN Transplant Coordinator will
Asymptomatic Elevated Liver Function Tests: Physiology, Chemistry, and Workup
Asymptomatic Elevated Liver Function Tests: Physiology, Chemistry, and Workup James T. Sing, Jr., D.O., FACG, AGAF Scott & White Clinic Assistant Professor Department of Internal Medicine Division of Gastroenterology
Hepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
Liver Diseases. An Essential Guide for Nurses and Health Care Professionals
Brochure More information from http://www.researchandmarkets.com/reports/1047385/ Liver Diseases. An Essential Guide for Nurses and Health Care Professionals Description: Liver disease is a rapidly growing
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
Drugs Believed Capable of Inducing Autoimmune Hepatitis
Drugs Believed Capable of Inducing Autoimmune Hepatitis Leonard B. Seeff, M.D. National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health Immune-Mediated Liver Diseases
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
Liver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
Case Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
Where Will my New Kidney Come From?
Where Will my New Kidney Come From? The Organ Shortage There is a severe shortage of organs for transplant. This means that the wait for a kidney transplant can be many years. The UW Transplant Program
Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
OMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s!
How to Interpret and Use Them René Romero, M.D. Clinical Director, Pediatric Hepatology CPG Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Objectives Understand the anatomy
Albumin. Prothrombin time. Total protein
Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis
Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis
Research Article Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis RR. Pawar*, ML. Pardeshi and BB. Ghongane Department of Pharmacology, B.J. Medical
HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
New IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
Treatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
Prof. of Tropical Medicine Faculty of Medicine Alexandria University
prof. Dr. Ali El-Kady (MD) Prof. of Tropical Medicine Faculty of Medicine Alexandria University DRUGS THAT MAY CAUSE LIVER DYSFUNCTION DAMAGE The liver is the principal organ that is capable of converting
*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS
The shortage of kidney donors and the ever-increasing waiting list has prompted the transplant community to look at different types of organ donors to meet the needs of our patients on the waiting list.
2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
Presented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch
Bass N.M., et. al. N Engl J Med 2010; 362:1071-1081 Presented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch Faculty Advisor: Dr. Fred
Molecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome
Biomedical & Pharmacology Journal Vol. 6(2), 259-264 (2013) The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome Vadod Norouzi 1, Ali
Hepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
PARACETAMOL POISONING
Background Resuscitation Risk Assessment Supportive Care Decontamination Paracetamol Levels Nomogram Antidote N-acetylcysteine (NAC) Table NAC infusion guide Timing of Investigations Risk factors for Paracetamol
Evaluation of a Child with Elevated Transaminases. Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium
Evaluation of a Child with Elevated Transaminases Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium Disclosures I do not have a financial interest, arrangement or affiliation
NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
Liver Function Tests. Dr Stephen Butler Paediatric Advance Trainee TDHB
Liver Function Tests Dr Stephen Butler Paediatric Advance Trainee TDHB Introduction Case presentation What is the liver? Overview of tests used to measure liver function RJ 10 month old European girl
Hepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
HBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
Hepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
HEPATITIS E VIRUS AND ALLOGENIC STEM CELL TRANSPLANTATION
Date 13 August 2015 Dear Colleague HEPATITIS E VIRUS AND ALLOGENIC STEM CELL TRANSPLANTATION We are seeing a significant increase in the number of reports of cases of hepatitis E virus (HEV) arising from
What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon
What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
Enzyme Replacement Therapies for UCD (Liver/ Liver Cell / Stem Cell Transplantation) Pat McKiernan Birmingham Children s Hospital
Enzyme Replacement Therapies for UCD (Liver/ Liver Cell / Stem Cell Transplantation) Pat McKiernan Birmingham Children s Hospital Survival following liver transplantation for Biliary Atresia at BCH (n=195)
Acute liver failure (ALF) is a potentially lifethreatening. Acute Liver Failure. R e s i d e n t G r a n d R o u n d s
R e s i d e n t G r a n d R o u n d s Acute Liver Failure Series Editor: Mark A. Perazella, MD Natravis R. Cox, MD, MPH Smruti R. Mohanty, MD, MS Acute liver failure (ALF) is a potentially life-threatening
LIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
1.How did I get Hepatitis C?
1.How did I get Hepatitis C? Sharing needles and syringes ( iv drug use ) or using contaminated straws to snort cocaine Reused needles or medications in a health care setting- (LV endoscopy outbreak, glucometers
LCD for Viral Hepatitis Serology Tests
LCD for Viral Hepatitis Serology Tests Applicable CPT Code(s): 86692 Antibody; Hepatitis, Delta Agent 86704 Hepatitis B Core Antibody (HBcAb); Total 86705 Hepatitis B Core Antibody (HBcAb); IgM Antibody
Focus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
Guidelines Most Significantly Affected Under ICD-10-CM. May 29, 2013
Guidelines Most Significantly Affected Under ICD-10-CM May 29, 2013 Guidelines Most Significantly Affected Under ICD-10-CM A look at the new system and how it compares to ICD-9-CM Presented by Therese
LAB 1 - Direct agglutination. Serology-the study of the in vitro reactions between antibody and antigen
LAB 1 - Direct agglutination Serology-the study of the in vitro reactions between antibody and antigen Serological reaction: - quantitative (weight/volume) - qualitative Agglutination - the aggregation
HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
